it rebounded in less than a year, a move credited to the company's prompt and aggressive reaction. In November, it reintroduced capsules in a new, triple-sealed package, coupled with heavy price promotions and within several years, Tylenol had regained the highest market share for the over-the-counter analgesic in the US. After the recall, Johnson & Johnson subsidiary McNeil Laboratories submitted a claim to its insurance company, Affiliated FM Insurance, for the cost of carrying out the recall, a claim which was later denied. A lawsuit determined that McNeil Laboratories was ultimately not covered because the parent company Johnson & Johnson elected not to buy more expensive recall insurance. McNeil sued again in court, further contending that the language of its excess liability insurance policy covered the recall and recall-related expenses. The court hearing that case rejected a claim of liability, stating that the recall "was not caused by liability for the seven deaths; it was at best merely related to the seven deaths in that they served as notice to the plaintiff that the Tylenol remaining on the shelves was potentially harmful." In 1991, Johnson & Johnson agreed to settle, for an undisclosed sum, all lawsuits against it for the original Chicago area deaths. Robert Kniffin, a spokesman for Johnson & Johnson, stated that "though there is no way we could have anticipated a criminal tampering with our product or prevented it, we wanted to do something for the families and finally get this tragic event behind us." The crisis management response, taught today as a model of corporate public relations, is chiefly credited to public relations executive Harold Burson. Pharmaceutical changes The 1982 incident inspired the pharmaceutical, food, and consumer product industries to develop tamper-resistant packaging, such as induction seals and improved quality control methods. Moreover, product tampering was made a federal crime. The new laws resulted in Stella Nickell's conviction in the Excedrin tampering case, for which she was sentenced to 90 years in prison. Additionally, the incident prompted the pharmaceutical industry to move away from capsules, which were easy to contaminate as a foreign substance could be placed inside without obvious signs of tampering. Within the year, the FDA introduced more stringent regulations to avoid product tampering. This led to the eventual replacement of the capsule with the solid "caplet", a tablet made in the shape of a capsule, as a drug delivery form and with the